Sequel Med Tech and Senseonics (SENS) Holdings announced full availability of the twiist Automated Insulin Delivery System integrated with the Eversense 365 CGM system across the U.S. Powered by Tidepool, twiist is the first AID system compatible with Eversense 365, the world’s only one-year CGM. This powerful combination is a significant leap forward for the diabetes community, offering a transformative solution for long-term diabetes management by significantly reducing the burden of frequent sensor changes and re-pairing while maintaining exceptional CGM accuracy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SENS:
- Senseonics announces CE Mark approval for Eversense 365 CGM system
- Senseonics Reports Record 2025 Revenue and Growth Milestones
- Senseonics sees FY25 revenue $58M-$62M, consensus $59.73M
- Senseonics sees Q4 revenue $14.2M, consensus $14.22M
- Senseonics reports first commercial patients using Eversense 365 CGM with twiist